ImmunityBio (IBRX) Stock Jumps as EU Clears ANKTIVA for Bladder Cancer

TLDR European Commission granted conditional approval for ANKTIVA with BCG for BCG-unresponsive NMIBC — a first for Europe. Approval covers 30 European countries, taking ANKTIVA’s total to 33 countries in four regulatory jurisdictions. QUILT-3.032 data: 71% complete response rate, 84% of responders cystectomy-free at 36 months. IBRX jumped 31% Wednesday, now up over 200% year-to-date. [...]

The post ImmunityBio (IBRX) Stock Jumps as EU Clears ANKTIVA for Bladder Cancer appeared first on Blockonomi.